Related Experiment Video
Updated: Aug 14, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment
A Hasenburg1, X W Tong, A Rojas-Martinez
1Department of Obstetrics and Gynecology, Freiburg University Medical Center, Germany.
Background:
In a Phase I study replication-deficient adenovirus containing the herpes simplex virus (HSV) thymidine kinase (TK) gene (AdV-HSV-TK) was instilled intraperitoneally in patients with recurrent ovarian cancer. Patients were treated with Acyclovir (ACV) or Valacyclovir (VCV) as enzymatic substrates. The purpose of this study was to compare serum levels of ACV and VCV.
Patients And Methods:
The antiherpetic prodrug and Topotecan (1.0 mg/m2 over 30 minutes each day for 5 days) were started 24 hours after vector application. Eight patients received ACV (15 mg/kg i.v. over one hour every 8 hours for 42 doses), two patients were started on ACV for 5 days and then switched to oral VCV (2 g every 8 hours for a total of 42 doses). Blood samples were obtained 20 minutes prior to each drug.
Results:
Serum levels of ACV and VCV (converted to ACV) were comparable.
Conclusions:
Suicide gene therapy with TK is under investigation in a variety of solid tumors. Replacing ACV by VCV will offer a cost-effective alternative and will significantly reduce duration of hospital stay improving quality of life and facilitating an outpatient gene therapy concept.
Related Concept Videos
Gene Therapy
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Tumor Immunotherapy
Antiviral Nucleoside Inhibitors

